Quoin Pharmaceuticals (NASDAQ:QNRX) COO Denise Carter Purchases 20,490 Shares

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) COO Denise Carter bought 20,490 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, August 31st. The stock was acquired at an average price of $4.88 per share, with a total value of $99,991.20. Following the acquisition, the chief operating officer directly owned 37,709 shares of the company’s stock, valued at approximately $184,019.92. This represents a 119.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Quoin Pharmaceuticals Stock Performance

Shares of QNRX stock traded up $0.29 on Tuesday, reaching $6.51. 274,471 shares of the company’s stock traded hands, compared to its average volume of 1,602,162. The company has a market capitalization of $13.09 million, a P/E ratio of -0.26 and a beta of 1.50. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a 12-month low of $3.25 and a 12-month high of $41.80. The business’s 50 day moving average price is $4.77 and its two-hundred day moving average price is $5.89.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings data on Friday, August 14th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.29). Research analysts predict that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on QNRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, July 20th. ThinkEquity assumed coverage on shares of Quoin Pharmaceuticals in a research note on Monday, June 15th. They issued a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Quoin Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Ikarian Capital LLC acquired a new position in Quoin Pharmaceuticals in the fourth quarter worth approximately $3,052,000. Millennium Management LLC bought a new position in Quoin Pharmaceuticals during the fourth quarter valued at approximately $1,080,000. SummitTX Capital L.P. acquired a new stake in Quoin Pharmaceuticals in the fourth quarter valued at approximately $935,000. Boothbay Fund Management LLC bought a new stake in Quoin Pharmaceuticals in the fourth quarter worth approximately $863,000. Finally, ADAR1 Capital Management LLC bought a new stake in Quoin Pharmaceuticals in the fourth quarter worth approximately $840,000. Institutional investors own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.